Clinical trials are a fundamental step in the development of Xencor’s monoclonal antibody therapeutics.

Clinical trials are research studies that are designed to determine if a medicine is safe and effective for patients. Patients may participate in ongoing clinical trials of Xencor’s investigational drug candidates if they meet certain enrollment criteria.

A Study of the Effect of XmAb5871 in Patients With Systemic Lupus Erythematosus

Condition: Systemic Lupus Erythematosus

Phase: Phase 2

The purpose of this study is to determine the ability of XmAb5871 to maintain Systemic Lupus Erythematosus (SLE) disease activity improvement achieved by a brief course of disease-suppressing steroid therapy

View

Study to Evaluate the Effect of XmAb5871 on Disease Activity in Patients With IgG4-Related Disease (RD)

Condition: IgG4-RD

Phase: Phase 2

The purpose of this Phase 2 study is to investigate the effect of XmAb5871 on IgG4-Related Disease (RD) activity

View

Safety and Tolerability of XmAb7195 in Adult Healthy Volunteers and Adult Subjects With a History of Allergic Rhinitis and/or Allergic Conjunctivitis and/or Atopic Dermatitis

Conditions: Allergic Rhinitis; Allergic Conjunctivitis; Atopic Dermatitis

Phase: Phase 1

This first-in-human (FIH) study is a randomized, double-blinded, placebo-controlled, ascending dose study to investigate the safety, tolerability, and pharmacokinetics of XmAb7195 in adult healthy volunteers and in adult subjects with elevated IgE levels.

View

PH 1 Study to Evaluate Safety and Tolerability of XmAb14045 in Patients With CD123-expressing Hematologic Malignancies

Conditions: Acute Myelogenous Leukemia (AML); B-cell Acute Lymohoblastic Leukemia (B-ALL); Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN); Chronic Myeloid Leukemia (CML in blast phase)

Phase: Phase 1

The purpose of this study if to determine the safety and tolerability of weekly intravenous (IV) administration of XmAb14045 and to determine the maximally tolerated dose (MTD) after the first dose, and then to determine the MTD after second and subsequent infusions.

View

Safety, Tolerability, and Bioavailability of Subcutaneously Administered XmAb7195

Conditions: Atopic Disease

Phase: Phase 1b

This is a Phase 1b, combined multiple dose subcutaneous (SC) bioavailability (BA) and multiple ascending dose (MAD) study evaluating safety, tolerability and BA of SC XmAb7195 in healthy subjects and in subjects with atopic disease.

View

Study to Evaluate Safety and Tolerability of XmAb13676 in Patients With CD20-expressing Hematologic Malignancies

Conditions: B-cell Non-Hodgkins Lymphoma; Chronic Lymphocytic Leukemia; Small Lymphocytic Lymphoma

Phase: Phase 1

This study will determine a dose and schedule for XmAb13676 in the treatment of CD20 expressing hematologic malignancies.

View

Information about Xencor’s clinical trials is available at www.clinicaltrials.gov.

Expanded Access Policy

CONTACT US

info@xencor.com
collaborate@xencor.com

Xencor, Inc. Headquarters
111 West Lemon Avenue,
2^nd floor
Monrovia, CA 91016
(626) 305-5900

Xencor, Inc. San Diego
12481 High Bluff Dr., Suite 200
San Diego, CA 92130
(858) 617-6155